Increased U.S. Generic Competition Offsets New Product Launches in Dr. Reddy’s Second Quarter
While U.S. generic drug price erosion was largely subdued relative to the first quarter of fiscal 2017, we expect the more competitive environment to persist, creating a new normal for Dr. Reddy’s U.S. generics business. Our model already incorporates these pricing headwinds offsetting the expected acceleration of product launches in the U.S. market, and we plan on maintaining our $38 (INR 2,560) per share fair value estimate. Despite the company’s recent pricing and regulatory woes, we believe ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.